Analysts Offer Insights on Healthcare Companies: Revance Therapeutics (NASDAQ: RVNC) and Celgene (NASDAQ: CELG)

By Austin Angelo

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Revance Therapeutics (RVNCResearch Report) and Celgene (CELGResearch Report).

Revance Therapeutics (RVNC)

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Revance Therapeutics, with a price target of $34.00. The company’s shares closed last Monday at $15.81.

According to TipRanks.com, Yang is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -2.9% and a 35.9% success rate. Yang covers the Healthcare sector, focusing on stocks such as Audentes Therapeutics, Xeris Pharmaceuticals, and Nektar Therapeutics.

Revance Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $33.33, implying an 113.0% upside from current levels. In a report issued on October 30, Wells Fargo also upgraded the stock to Buy with a $20.00 price target.

See today’s analyst top recommended stocks >>

Celgene (CELG)

Mizuho Securities analyst Salim Syed maintained a Hold rating on Celgene today and set a price target of $100.00. The company’s shares closed last Monday at $107.80, close to its 52-week high of $109.07.

According to TipRanks.com, Syed ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.1% and a 47.5% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences.

The word on The Street in general, suggests a Hold analyst consensus rating for Celgene with a $107.00 average price target, implying a -0.7% downside from current levels. In a report issued on November 1, Robert W. Baird also downgraded the stock to Hold with a $101.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.